Ixekizumab
Based on 3 publication(s) in Google Scholar
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.00%
- CAS. Nr.: 1143503-69-8
- Molecular Weight:146.44 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Ixekizumab
More
Biologische Aktivität
Human IgG4 kappa
Human
|
IL-17 |
The equilibrium KD of Ixekizumab for human and cynomolgus monkey IL-17A were 1.8 pM and 0.8 pM, respectively. Ixekizumab also bound to rabbit IL-17A, but the affinity was lower, and the binding was heterogeneous (KD of 1.3 nM and 14 nM). Ixekizumab shows no binding to either mouse or rat IL-17A[1].
Ixekizumab (0.1-10000 pM) inhibits human IL-17A- or human IL-17A/F heterodimer-induced growth-regulated oncogene (GRO)α secretion from HT-29 cells in a dose-dependent fashion. Ixekizumab inhibits cynomolgus monkey IL-17A-induced GROα secretion from HT-29 cells in a dose-dependent fashion[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In male cynomolgus monkeys, following IV administration of 1 mg/kg, Ixekizumab is eliminated with a mean half-life of 6.5 days. After SC administration of 1 mg/kg, Ixekizumab reaches an average maximal plasma concentration of 11.1 μg/mL ~72 hours postdose. The mean elimination half-life following the SC injection was 10.3 days[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice (n=5 per group, 8-12-week old, subcutaneous injection of human IL-17A)[1]
-
Dosage:1 mg/kg, 0.1 mg/kg, 0.01 mg/kg, or 0.001 mg/kg (corresponding to 20 µg, 2 µg, 0.2 µg, and 0.02 µg per mouse, respectively)
-
Administration:I.v.; 1 hour prior to a subcutaneous (SC) injection of human IL-17A
-
Result:Decrease human IL-17A-induced KC secretion in the plasma of the C57BL/6 mice in a dose-dependent manner.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Immobilized IL-17A Protein, Human (HEK293, His, HY-P70527) can bind Ixekizumab. The EC50 for this effect is 4.97 ng/mL. -
Flow cytometric analysis of 1X106 Jurkat cells with Ixekizumab (HY-P9924, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 (S228P) kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS. Nr. 1143503-69-8
-
Appearance Liquid
-
Molecular Weight 146.44 kDa
-
Color Colorless to light yellow
-
SMILES
[Ixekizumab]
-
Synonyms
LY2439821
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
β-elemene directly targets IL-17RA in macrophages to inhibit inflammation and attenuate acute pancreatitis. [Abstract]2026 Jun 24:159:158478. PMID: 42365689 -
-
BMC Vet Res
Echinatin attenuates LPS-induced mastitis by suppressing IL-17RA and MAPK/NF-κB signaling. [Abstract]2026 May 28. PMID: 42210240
Reinheit & Dokumentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Liu L, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39-50. Published 2016 Apr 19. [Content Brief]
[2]. Griffiths CE, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541-551. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Ixekizumab Related Classifications
HY-P9924 Related Classifications
Powered by Bioz